182 related articles for article (PubMed ID: 32753678)
21. Expression of the SART3 tumor rejection antigen in renal cell carcinoma.
Kawagoe N; Shintaku I; Yutani S; Etoh H; Matuoka K; Noda S; Itoh K
J Urol; 2000 Dec; 164(6):2090-5. PubMed ID: 11061933
[TBL] [Abstract][Full Text] [Related]
22. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
[TBL] [Abstract][Full Text] [Related]
23. Enhanced ADCC activity of affinity maturated and Fc-engineered mini-antibodies directed against the AML stem cell antigen CD96.
Mohseni Nodehi S; Repp R; Kellner C; Bräutigam J; Staudinger M; Schub N; Peipp M; Gramatzki M; Humpe A
PLoS One; 2012; 7(8):e42426. PubMed ID: 22879978
[TBL] [Abstract][Full Text] [Related]
24. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact and immunogenicity of a novel osteosarcoma antigen, papillomavirus binding factor, in patients with osteosarcoma.
Tsukahara T; Kawaguchi S; Torigoe T; Kimura S; Murase M; Ichimiya S; Wada T; Kaya M; Nagoya S; Ishii T; Tatezaki S; Yamashita T; Sato N
Cancer Sci; 2008 Feb; 99(2):368-75. PubMed ID: 18271936
[TBL] [Abstract][Full Text] [Related]
26. Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma.
Komohara Y; Harada M; Arima Y; Suekane S; Noguchi M; Yamada A; Itoh K; Matsuoka K
Int J Oncol; 2006 Dec; 29(6):1555-60. PubMed ID: 17088996
[TBL] [Abstract][Full Text] [Related]
27. Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen.
Low L; Goh A; Koh J; Lim S; Wang CI
Nat Commun; 2019 Nov; 10(1):5382. PubMed ID: 31772160
[TBL] [Abstract][Full Text] [Related]
28. Isolation of scFv antibody fragments against HER2 and CEA tumor antigens from combinatorial antibody libraries derived from cancer patients.
Ayat H; Burrone OR; Sadghizadeh M; Jahanzad E; Rastgou N; Moghadasi S; Arbabi M
Biologicals; 2013 Nov; 41(6):345-54. PubMed ID: 23845693
[TBL] [Abstract][Full Text] [Related]
29. Dual display: phage selection driven by co-engagement of two targets by two different antibody fragments.
Fagète S; Botas-Perez L; Rossito-Borlat I; Adea K; Gueneau F; Ravn U; Rousseau F; Kosco-Vilbois M; Fischer N; Hartley O
Protein Eng Des Sel; 2017 Sep; 30(9):575-582. PubMed ID: 28444391
[TBL] [Abstract][Full Text] [Related]
30. WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma.
Iiyama T; Udaka K; Takeda S; Takeuchi T; Adachi YC; Ohtsuki Y; Tsuboi A; Nakatsuka S; Elisseeva OA; Oji Y; Kawakami M; Nakajima H; Nishida S; Shirakata T; Oka Y; Shuin T; Sugiyama H
Microbiol Immunol; 2007; 51(5):519-30. PubMed ID: 17579261
[TBL] [Abstract][Full Text] [Related]
31. Conversion of scFv peptide-binding specificity for crystal chaperone development.
Pai JC; Culver JA; Drury JE; Motani RS; Lieberman RL; Maynard JA
Protein Eng Des Sel; 2011 May; 24(5):419-28. PubMed ID: 21217145
[TBL] [Abstract][Full Text] [Related]
32. A fully human scFv phage display library for rapid antibody fragment reformatting.
Li K; Zettlitz KA; Lipianskaya J; Zhou Y; Marks JD; Mallick P; Reiter RE; Wu AM
Protein Eng Des Sel; 2015 Oct; 28(10):307-16. PubMed ID: 25991864
[TBL] [Abstract][Full Text] [Related]
33. DNAJB8 in small extracellular vesicles promotes Oxaliplatin resistance through TP53/MDR1 pathway in colon cancer.
Wang Z; Li Y; Mao R; Zhang Y; Wen J; Liu Q; Liu Y; Zhang T
Cell Death Dis; 2022 Feb; 13(2):151. PubMed ID: 35165262
[TBL] [Abstract][Full Text] [Related]
34. Development of T cell receptor-engineered T cells targeting the sarcoma-associated antigen papillomavirus binding factor.
Hamada S; Tsukahara T; Watanabe Y; Murata K; Mizue Y; Kubo T; Kanaseki T; Hirohashi Y; Emori M; Nakatsugawa M; Teramoto A; Yamashita T; Torigoe T
Cancer Sci; 2024 Jan; 115(1):24-35. PubMed ID: 37879364
[TBL] [Abstract][Full Text] [Related]
35. Dendritic-cell-based immunotherapy evokes potent anti-tumor immune responses in CD105+ human renal cancer stem cells.
Zhang XF; Weng DS; Pan K; Zhou ZQ; Pan QZ; Zhao JJ; Tang Y; Jiang SS; Chen CL; Li YQ; Zhang HX; Chang AE; Wicha MS; Zeng YX; Li Q; Xia JC
Mol Carcinog; 2017 Nov; 56(11):2499-2511. PubMed ID: 28621442
[TBL] [Abstract][Full Text] [Related]
36. [Cloning and expression of human single-chain Fv antibody against A beta(1-42) peptide involved in Alzheimer disease].
Jia J; Liu Z; Zhao XM; Liang P
Zhonghua Bing Li Xue Za Zhi; 2008 Jun; 37(6):400-4. PubMed ID: 19031720
[TBL] [Abstract][Full Text] [Related]
37. An HLA-modified ovarian cancer cell line induced CTL responses specific to an epitope derived from claudin-1 presented by HLA-A*24:02 molecules.
Kondo S; Demachi-Okamura A; Hirosawa T; Maki H; Fujita M; Uemura Y; Akatsuka Y; Yamamoto E; Shibata K; Ino K; Kikkawa F; Kuzushima K
Hum Immunol; 2013 Sep; 74(9):1103-10. PubMed ID: 23806269
[TBL] [Abstract][Full Text] [Related]
38. Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients.
Kobayashi K; Noguchi M; Itoh K; Harada M
Cancer Sci; 2003 Jul; 94(7):622-7. PubMed ID: 12841872
[TBL] [Abstract][Full Text] [Related]
39. A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes.
Ikuta Y; Okugawa T; Furugen R; Nagata Y; Takahashi Y; Wang L; Ikeda H; Watanabe M; Imai S; Shiku H
Int J Cancer; 2000 Aug; 87(4):553-8. PubMed ID: 10918197
[TBL] [Abstract][Full Text] [Related]
40. Identification of novel MAGE-A6- and MAGE-A12-derived HLA-A24-restricted cytotoxic T lymphocyte epitopes using an in silico peptide-docking assay.
Akiyama Y; Komiyama M; Nakamura Y; Iizuka A; Oshita C; Kume A; Nogami M; Miyata H; Ashizawa T; Yoshikawa S; Kiyohara Y; Yamaguchi K
Cancer Immunol Immunother; 2012 Dec; 61(12):2311-9. PubMed ID: 22707303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
